Next-Generation Gynecological Cancer Diagnostics Market Size, Share & Trends Analysis Report By Technology (Next generation sequencing, Polymerase chain reaction (PCR), DNA Microarrays, Multiplexing, Protein Microarrays, Others), By Cancer Type (Breast, Lung, Colorectal, Prostate, Cervical, Others), By Function (Cancer Screening, Therapeutic Monitoring, Risk Analysis) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Next-Generation Gynecological Cancer Diagnostics Market Size & Growth Analysis

The global next-generation gynecological cancer diagnostics market size was valued at USD 17.98 billion in 2025 and is projected to grow from USD 19.95 billion in 2026 to USD 45.77 billion by 2034, registering a CAGR of 10.94% during the forecast period from 2026 to 2034. North America dominated the next-generation gynecological cancer diagnostics market with a market share of 40.93% in 2025.

Technology Insights

The next-generation sequencing (NGS) segment dominated the market in 2025 with a revenue share of 36.74%, due to the increasing adoption of multi-gene panel testing and personalized treatment planning, coupled with advancements in high-throughput sequencing technologies, greater clinical accuracy, and growing awareness among healthcare providers and patients about the benefits of precision oncology.

Polymerase chain reaction (PCR) is anticipated to register the fastest CAGR of 11.34%, during the forecast period, owing to its high sensitivity and specificity in detecting low levels of tumor DNA, RNA, or specific mutations, which is crucial for early cancer detection and monitoring minimal residual disease.

Request Customizationto receive a tailored report.

Type Insights

The breast cancer segment is anticipated to grow at a CAGR of 11.70% during 2026-2034, owing to the rising awareness of hereditary breast cancer and the focus on development of targeted therapies for its treatment.

The lung cancer segment dominated the market in 2025, with a revenue share of 46.24%, owing to growing incidence of smoking-related and environmental risk factors, advancements in minimally invasive diagnostic techniques, and the rising availability of companion diagnostic tests. Increased investment in research for novel biomarkers and targeted therapies has also accelerated the adoption of next-generation diagnostics.

Function Insights

The cancer screening dominated the market in 2025, with a revenue share of 45.23%. The growth is attributed to the rising cancer prevalence and strong government initiatives promoting early detection programs. Moreover, the adoption of advanced diagnostics is driving the cancer screening segment’s growth by improving outcomes and enabling timely treatment interventions.

The therapeutic monitoring segment is expected to register the fastest CAGR of 11.21% during the forecast period, owing to the increasing adoption of targeted therapies and immunotherapies in cancer treatment, which has further enhanced the demand for efficient therapeutic monitoring. These advanced treatment modalities often require close monitoring to evaluate their impact on the tumor and ensure optimal patient outcomes.

Speak to an Analystto discuss market opportunities.

Regional Analysis

The North America region dominated the market with a revenue share of 40.93% in 2025. The growth is attributed to factors such as widespread adoption of liquid biopsy NGS tests for early cancer detection which improved diagnostic accuracy, enabled minimally invasive testing, and enhanced higher clinical acceptance across oncology practices, further strengthening the region’s leadership in next-generation cancer diagnostics.

The next-generation cancer diagnostics market in U.S. is widely driven by Medicare’s coverage of FDA-approved NGS tests for advanced cancer. This policy ensured that patients get reimbursed for next generation sequencing tests, which hence made the tests more affordable. This unique step expanded access, increased adoption, and boosted market size, as well as strongly supported overall next-generation cancer diagnostics market growth.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific Market Insights

The Asia Pacific region is the fastest-growing region with a CAGR of 13.01% during the forecast timeframe. The growth is attributed to factors such as government funding for cancer genomics research in Japan and South Korea which has accelerated advancements clinical adoption, and fostered collaborations between research institutions and industry players, while also creating opportunities for early detection programs, and expansion of next generation diagnostic technologies across emerging economies in the region.

India continues to position itself in the next-generation cancer diagnostics market, due to the low-cost access to advanced NGS tests for lung cancer. In 2024, AstraZeneca India and RGCI&RC jointly launched a dedicated center that offered a 34-gene panel NGS test at subsidized rates. This initiative not only improved patient access to precision diagnostics but also enhanced awareness, which further contributed to expanding the overall market growth in the country.

Europe Market Insights

A major driving factor for the European next-generation cancer diagnostics market is the region’s rapid digitalization of healthcare and integration of artificial intelligence (AI) in diagnostic workflows. The implementation of the Digital Healthcare Act (DVG) and growing investments in AI-enabled pathology and imaging platforms are transforming cancer diagnostics into a more data-driven and precise process. Hospitals and diagnostic centers are increasingly adopting digital pathology systems and cloud-based genomic analysis tools that enable faster and more accurate interpretation of tumor profiles.

The next-generation cancer diagnostics market growth is propelling due to the research and development in this field, which is further accelerating market growth, with companies heavily investing in R&D and leveraging government funding to advance oncology diagnostics. This strong focus on development is driving higher adoption of NGS-based cancer diagnostics, further contributing to overall market expansion. The trend is clearly reflected in the rising investment patterns, as depicted in the graph below, which illustrates Cancer Research UK’s spending on ongoing and new cancer research in 2023:

Middle East and Africa Market Insights

In the Middle East and Africa, a unique driving factor for the next-generation cancer diagnostics market is the rising demand for non-invasive and rapid diagnostic solutions due to limited access to advanced oncology facilities in several regions. Several countries are adopting portable molecular testing technologies to overcome challenges associated with traditional tissue biopsies, such as the lack of specialized laboratories and pathologists. For instance, the United Arab Emirates and South Africa are introducing point-of-care genomic testing initiatives to expand cancer screening and early detection in remote areas.

In South Africa, a distinctive driving factor for the next-generation cancer diagnostics market is the increasing integration of oncology diagnostics within public and private research collaborations aimed at addressing the country’s diverse genetic landscape. South Africa’s population exhibits genetic heterogeneity, which has prompted local research institutions to prioritize genomic studies tailored to African populations. Initiatives such as the South African National Bioinformatics Institute (SANBI) and collaborations with the South African Medical Research Council (SAMRC) are supporting the development of region-specific cancer biomarkers and molecular diagnostic assays.

Latin America Market Insights

In Latin America, a key driving factor for the next-generation cancer diagnostics market is the expansion of regional manufacturing and localization of diagnostic technologies to reduce dependency on imports and improve affordability. Several countries, including Brazil, Mexico, and Argentina, promoted domestic production of molecular testing reagents, sequencing kits, and diagnostic instruments through public-private partnerships and government-backed funds. For instance, Brazil’s Ministry of Health has supported initiatives under the Productive Development Partnerships (PDPs) program to enhance local manufacturing of precision diagnostic tools, including next-generation sequencing (NGS) assays for oncology applications.

In Mexico, the driving factor for the next-generation cancer diagnostics market is the increasing focus on population-specific biomarker research to address regional cancer prevalence patterns. Mexican research institutions and universities conducted studies to identify genetic mutations and molecular markers that are more prevalent in Latin American populations, enabling the development of more accurate and tailored diagnostic tests. For example, collaborations between the National Institute of Genomic Medicine (INMEGEN) and private biotech firms led to the creation of targeted NGS panels for breast, cervical, and gastric cancers, which are among the most common in the region. This emphasis on locally relevant genomic data boosted the adoption of advanced cancer diagnostic technologies across Mexico.

Competitive Landscape

The global next-generation cancer diagnostics market is highly fragmented, with numerous players focusing on niche technologies, regional markets, and specialized diagnostic solutions.

Burning Rock Dx: An emerging market player

Burning Rock Dx, is an emerging player in the next-generation cancer diagnostics market, specializing in precision oncology through NGS-based diagnostics, companion diagnostics development, and early cancer detection.

• In October 2024, Burning Rock Dx announced that its OncoCompass Focus CDx test, which detected 9 major gene mutations, and was approved by China’s National Medical Products Administration (NMPA). The test was used as a companion diagnostic with Dizal’s targeted therapy, sunvozertinib for patients with EGFR exon 20 insertion mutations.

List of Key and Emerging Players in Next-Generation Gynecological Cancer Diagnostics Market